
- Pharmaceutical Technology-01-02-2017
- Volume 41
- Issue 1
Vials Reduce Risk of Drug Container Interactions
The DualFUSION vials from Wheaton for the storage of lyophilized materials are engineered using a plasma enhanced chemical vapor deposition technology to fuse an organosilicate protective layer with silica-like barrier layer, and then fuses that inner material to a cyclic olefin polymer outer shell.
The DualFUSION vials from Wheaton for the storage of lyophilized materials are engineered using a plasma enhanced chemical vapor deposition technology to fuse an organosilicate protective layer with silica-like barrier layer, and then fuses that inner material to a cyclic olefin polymer outer shell. The inert silica-like barrier layer of the vial is impermeable to oxygen and other gases from the surrounding environment, and protects against delamination and leaching of contaminants, reducing the risk of drug-container interactions. The protection provided by the innovation composition and construction of DualFUSION vials minimizes caking that can occur in lyophilized drug products.
DualFUSION vials can withstand a temperature range of -196 oC to 121 oC without cracking. A unique 2D barcode laser etched onto the bottom of each DualFUSION vial facilitates sample identification and product lot traceability. The vials can be used in the manufacture of proteins, peptides, enzymes, DNA, and RNA--of complex formulations that may be sensitive to oxygen or metal ion exposure--and of highly potent and radioactive substances.
Articles in this issue
over 9 years ago
Predicting Moisture Uptake in Solid Dosage Packagingover 9 years ago
Blister Packaging Moves Forwardover 9 years ago
Staffing and Preparation for Auditsover 9 years ago
Automatic Purge System for Control Panelsover 9 years ago
Fully Automated Capping Systemsover 9 years ago
Spray Dryer for Efficient Microencapsulationover 9 years ago
The Tide Stays Highover 9 years ago
Drug Quality Key to Innovation and Accessover 9 years ago
FDA New Drug Approvals Down Significantly in 2016over 9 years ago
Beyond Distractions, Pharma Moves On



